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Abstract
Active vaccination can be effective as a post-exposure prophylaxis, but the rapidity of the immune response
induced, relative to the incubation time of the pathogen, is critical. We show here that CD40mAb conjugated to
antigen induces a more rapid specific antibody response than currently used immunological adjuvants, alum and
monophosphoryl lipid A™.
Findings
Post-exposure prophylaxis (PEP), or the induction of
protection against an infectious disease after exposure to
the pathogen, is either utilised or has been suggested as
an appropriate course of action for a number of dis-
eases, including rabies [1], anthrax [2], varicella [3,4],
HIV and Hepatitis A [5]. PEP can be divided into three
categories: The administration of antibiotics or antivir-
als, passive immunization using specific immunoglobu-
lin, and active immunization (vaccination).
In some cases appropriate antimicrobial chemotherapy
may not be available, or there may be a worry that the
pathogen could be resistant to the agent, particularly in
bioterrorism cases. Passive immunization using immu-
noglobulin may be a suitable alternative, if the pathogen
is susceptible to antibody-mediated killing. However,
active vaccination has the potential advantages of lower
cost, less risk of adventitious pathogen transfer, and
most importantly the induction of long-term protection.
The use of active vaccination as PEP however depends
upon the rapidity with which a protective immune
response can be generated, in comparison with the incu-
bation period of the pathogen post-exposure. The
kinetics of the immune response are therefore a
potential rate-limiting step for the efficacy of post-expo-
sure vaccination.
Immune responses against vaccines are enhanced by
immunological adjuvants. Aluminum salts are the only
widely licensed immunological adjuvants [6], but the
adjuvant monophosphoryl lipid A (MPL™) is now
licensed in some countries for use in the cervical cancer
vaccine, Cervarix™ [7] and may shortly be licensed for
use in a wider range of vaccines. Aside from MPL™,
there is a large amount of research ongoing into other
potential adjuvants, including host co-stimulatory mole-
cules [8], TLR agonists [6,9], other particulate carriers
[10,11] and combinations of these approaches [12,13].
Agonistic antibodies against the antigen presenting
cell surface antigen CD40 are able to mimic the effect
of binding of the ligand, CD154, both in vitro [14] and
in vivo [15]. We have shown that agonistic CD40mono-
clonal antibody (mAb) is an effective immunological
adjuvant at low doses when chemically conjugated to
antigen. It is able to enhance antibody [16,17] as well as
T helper responses [18]. CD40 antibody or ligand is also
being investigated in cancer therapy and vaccination
[19,20]. As we believe CD40mAb conjugate acts as an
adjuvant at least in part via a direct effect on B cells
[21], we were interested in assessing the rapidity of the
antibody response induced by CD40mAb in comparison
with other adjuvants. We used the model antigen, oval-
bumin, in order to compare the kinetics of the induced* Correspondence: a.w.heath@shef.ac.uk
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antibody response between CD40 conjugate, MPL™ and
the widely used alum adjuvant.
Female C57Bl/6 mice aged 6-8 weeks were obtained
from Harlan UK Ltd and housed in accordance with
strict Home Office guidelines. Ovalbumin (Sigma) was
conjugated to the CD40mAb 10C8 [22] as previously
described [16]. Four groups of 15 mice were immunised
intraperitoneally with either 10 μg of conjugate, 10 μg of
ovalbumin either alone, with MPL™ (10 μg, Sigma) or
adsorbed onto Aluminium hydroxide (200 μg, 5). Five of
the 15 mice were bled every 3 days in rotation, and
anti-ovalbumin IgG endpoint titers determined by
ELISA assay as previously described [16]
ELISA results are shown in Fig 1. CD40mAb conju-
gate induced an IgG response against OVA by day 7
post immunization, whereas no IgG response to OVA
+MPL™ or OVA+alum was seen until day 8, and in the
case of alum this was weak. The results shown are
representative of a total of three experiments. Total
immunoglobulin responses (including IgM) tended to
Figure 1 C57Bl/6 mice were immunized once, as described in the text, with ovalbumin and the adjuvant shown at the top of the
figure, and bled at various days post-immunization (shown on left side of figure). ELISA data are plotted for 5 mice in each case with the
reciprocal of the serum dilution on the x axis, and optical density at 490 nm on the y axis. Note the scale of the y axis varies by row. Response
to CD40mAb adjuvanted vaccine was significantly better than the response to MPL or alum at day 7 (p < 0.05, One-way ANOVA with Dunnet’s
post-test).
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arise a day earlier, but showed the same difference in
kinetics between CD40 and the other two adjuvants.
CD40mAb-OVA conjugate induces a more rapid IgG
response in mice than either the established adjuvant,
alum, or the newer adjuvant, MPL™. How much faster
the response to a CD40mAb vaccine versus an MPL
adjuvanted vaccine would be in humans would need to
be determined empirically. How important a more rapid
response would be would depend upon the titers
required to protect against a particular pathogen, as well
as the window of opportunity available to prevent dis-
ease. We propose that CD40mAb conjugates may have
utility in post-exposure prophylaxis when a rapid anti-
body response is desirable.
Abbreviations used
MPL: monophosphoryl lipid A; TLR: Toll like receptor;
ELISA: Enzyme linked immunosorbent assay; PEP: post-
exposure prophylaxis; mAb: monoclonal antibody.
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